Literature DB >> 29211401

Extrarenal Angiomyolipoma: differential diagnosis of retroperitoneal masses.

Marcelo Langer Wroclawski1, Willy Baccaglini2, Cristiano Linck Pazeto2, Cristina Carbajo2, Chaline Matushita2, Arie Carneiro2, Alexandre Pompeo2, Sidney Glina2, Antonio Carlos Lima Pompeo2, Lívia Barreira Cavalcante3.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 29211401      PMCID: PMC5996806          DOI: 10.1590/S1677-5538.IBJU.2016.0670

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


× No keyword cloud information.

INTRODUCTION

Angiomiolipomas (AML) are benign mesenchymal tumors of unknown origin, that consist of mature adipose tissue, muscle fibers and blood vessel with thickened wall (1). Renal AMLs represent 1% of renal tumors. However, extra-renal AMLs are extremely rare, and 60 cases have been described. Most extra-renal AMLs were observed at liver (18 patients) and at retroperitoneum (16 cases) (2). We report a retroperitoneum extra-renal AML.

CASE REPORT

A fifty-one years old man with right lumbar pain for one day was submitted to computer tomography that showed an incidental left retroperitoneal nodule, in close contact to ipsilateral adrenal gland. Magnetic resonance confirmed the presence of a heterogeneous nodule, close to left adrenal, hypervascularized, with sparse focus with loss of signal in sequences with fat saturation, with approximately 2.4x2.1cm (Figures 1 and 2). Blood analysis excluded a functional adrenal tumor.
Figure 1

Magnetic ressonance with axial T1WI image in phases before contrast (A), arterial (B), Portal (C) and Equilibrium (D), showing a heterogenous nodule, hypervascularized, with peripheral progressive highlight due to contrast at the retroperitoneum, measuring 2.4x2.1cm.

Figure 2

Magnetic resonance images (ECO Gradient sequences GRE) T1W1 inside and outside of phase (A and B) and in T2 with and without fat suppression (C and D); they show sparse areas of signal loss corresponding to lipomatous foci.

The lesion was excised by transperitoneal laparoscopy without complications, and it was diagnosed a mesenchymal lesion compatible to AML, confirmed by immune-histochemical assay (Table-1 and Figure-3).
Table 1

Immuno-histochemical results that confirm angiomiolipoma.

ANTIGENRESULT
HMB45Reactivity in rare cells
Melan ANegative
CD34Positive
Smooth muscle actinePositive
Figure 3

A) triphasic tumor, including mature adipose tissue, blood vessels with thickened wall and smooth muscle cells; B) component of elongated smooth muscle cells irradiating from gibbous vessels walls, permeating adipose tissue; c) angiomiolipoma, interface between mature fat cells and smooth muscle cells without atypia.

DISCUSSION

AMLs are mainly asymptomatic incidentalomas. However, it was reported spontaneous bleeding (particularly in tumors with >4cm diameter), thromboembolic events and compression of adjacent structures (3–6). Also, the risk of malignization of such tumors is unknown. Most reported retroperitoneal AMLs include symptomatic and big tumors (2); the present tumor was a small incidental lesion. Image exams with presence of macroscopic fat are not conclusive, since liposarcoma represent most of retroperitoneal sarcomas adjacent to adrenal gland that can be confused to myelolipoma, particularly in well-defined lesions such as the one here described (7). Other possible diagnosis include lipomas, lymphoma, adenocarcinoma metastasis and germ cell tumors, extra-gonadal dermoid cyst, hibernomas and lipoblastomas, among others (8). Percutaneous biopsy may be inconclusive; therefore, treatment of choice must be excision, preferably by minimally invasive technique. In the present case, lesion excision allowed histologic confirmation, preclude follow-up with image exams and had low morbidity to patient. It is not uncommon the need of immune-histochemical exams for diagnosis, due to histologic similarities with other tumors, such as liposarcoma, leiomyoma and lipoma (9).
  9 in total

1.  A case of angiomyolipoma presenting as a huge retroperitoneal mass.

Authors:  M Tsutsumi; A Yamauchi; S Tsukamoto; S Ishikawa
Journal:  Int J Urol       Date:  2001-08       Impact factor: 3.369

2.  Aggressive renal angiomyolipoma extending into the renal vein and inferior vena cava - an uncommon entity.

Authors:  S S Bakshi; K Vishal; V Kalia; J S Gill
Journal:  Br J Radiol       Date:  2011-08       Impact factor: 3.039

3.  Computerized tomography characteristics that differentiate angiomyolipomas from liposarcomas in the perinephric space.

Authors:  Li-Jen Wang; Yon-Cheong Wong; Chi-Jen Chen; Lai-Chu See
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

Review 4.  Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm.

Authors:  C Messiou; E Moskovic; D Vanel; C Morosi; R Benchimol; D Strauss; A Miah; H Douis; W van Houdt; S Bonvalot
Journal:  Eur J Surg Oncol       Date:  2016-12-09       Impact factor: 4.424

Review 5.  [Extrarenal angiomyolipoma with spontaneous rupture: a case report].

Authors:  Masahiko Inahara; Kazushiro Takei; Hitoshi Naito; Masanobu Eguchi
Journal:  Hinyokika Kiyo       Date:  2008-07

6.  Renal colic due to fatty tissue obstruction of the ureter following selective arterial embolisation of a 10 cm angiomyolipoma.

Authors:  Jean Rouffilange; Aurélien Forgues; Nicolas Grenier; Grégoire Robert
Journal:  BMJ Case Rep       Date:  2015-07-29

7.  Spontaneous perinephric hemorrhage from extrarenal angiomyolipoma.

Authors:  R F Randazzo; P Neustein; M A Koyle
Journal:  Urology       Date:  1987-04       Impact factor: 2.649

8.  Fat-containing lesions of the retroperitoneum: radiologic-pathologic correlation.

Authors:  William D Craig; Julie C Fanburg-Smith; Leonard R Henry; Rubén Guerrero; Joel H Barton
Journal:  Radiographics       Date:  2009 Jan-Feb       Impact factor: 5.333

9.  Retroperitoneal extrarenal angiomyolipomas: an evidence-based approach to a rare clinical entity.

Authors:  Emmanuel J Minja; Megan Pellerin; Nicole Saviano; Ronald S Chamberlain
Journal:  Case Rep Nephrol       Date:  2012-07-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.